The Respiratory segment is one of the key segments from AstraZeneca’s (AZN) growth platforms. This segment reported a 9% decline in revenues at constant exchange rates to $1.1 billion during 2Q17. The products included in this segment include Symbicort, Pulmicort, Daliresp, Tudorza, Duaklir, and Bevespi.
Symbicort is a drug for the prevention of bronchospasm. Symbicort reported revenues of $706 million during 2Q17, an 11% decline in revenues at constant exchange rates compared to 2Q16. At constant exchange rates, its revenues fell 17% in its US sales and an 11% decrease in its sales in the European region, partially offset by 3% growth in emerging markets.
Pulmicort, a drug for the prevention of asthma attacks, reported revenues of $226 million during 2Q17, a 3% decline at constant exchange rates compared to 2Q16. At constant exchange rates, the US markets reported a decline of 26% in revenues to $37 million.
The European markets reported a 12% decline in revenues to $22 million, as well as a 5% decline in revenues from established rest of the world to $21 million, partially offset by 8% growth in revenues to $146 million.
Other drugs in the Respiratory segment include Daliresp, Tudorza/Eklira, Duaklir, and Bevespi. Eklira and Duaklir were added to AstraZeneca’s portfolio from its deal with Almirall.
AstraZeneca had acquired Tudorza and Daliresp from Allergan (AGN). Daliresp reported revenue growth of 20% to $48 million in 2Q17, while Tudorza/Eklira reported a 27% decline in revenues to $34 million in 2Q17. Duaklir reported flat revenues at $16 million during 2Q17, while Bevespi, a new drug, reported revenues of $3 million during 2Q17.
To divest company-specific risks, investors can consider the Vanguard International High Dividend Yield ETF (VYMI), which holds 0.7% of its total assets in AstraZeneca Plc (AZN). VYMI also holds 1.0% in GlaxoSmithKline (GSK), 1.0% in Sanofi (SNY), and 2.0% in Novartis (NVS).